1. Show article details.

    Hologic and Mary J. Blige Launch “Good Morning Gorgeous” Sweepstakes as a Wake-up Call to Increase Awareness of the Importance of Preventive Care

    Business Wire – 8:01 AM ET 08/12/2022

    --Leader in Women’s Health and Presenting Sponsor of Mary J. Blige’s “Good Morning Gorgeous” Tour Offers Fans a Chance to Win Tickets to Concerts Taking Place Across the Nation this Fall-- Hologic, Inc. (HOLX), a global leader in women’s health, and Grammy award-winning and Oscar-nominated artist, producer, and entrepreneur Mary J. Blige today announced the launch of the “Good Morning Gorgeous” sweeps...

  2. Show article details.

    U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights

    Business Wire – 6:06 PM ET 08/11/2022

    Hologic, Inc. (HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic (HOLX). “We are pleased that the U.S. Court of Appeals has once again ruled in our favor.

  3. Show article details.

    Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology

    PR Newswire – 11:30 PM ET 07/31/2022

    CARLSBAD, Calif. Details about Active Motif's proprietary Cut&Tag-IT TM technology can be found at www.activemotif.com/catalog/1318/cut-tag-it-kit. About Active MotifActive Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Media Contact: Fritz Eibel, Active Motif Incorporated, Feibel@activemotif.com.

  4. Show article details.

    Hologic's Return On Capital Employed Overview

    Benzinga – 11:47 AM ET 07/28/2022

    Pulled from Benzinga Pro data, Hologic posted Q3 earnings of $228.40 million, an increase from Q2 of 49.88%. Sales dropped to $1.00 billion, a 30.15% decrease between quarters. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

  5. Show article details.

    Recap: Hologic Q3 Earnings

    Benzinga – 5:44 PM ET 07/27/2022

    Hologic reported its Q3 earnings results on Wednesday, July 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Hologic beat estimated earnings by 33.8%, reporting an EPS of $0.95 versus an estimate of $0.71. Revenue was down $165.00 million from the same period last year.

  6. Show article details.

    Hologic Announces Financial Results for Third Quarter of Fiscal 2022

    Business Wire – 4:02 PM ET 07/27/2022

    – Revenue of $1.003 Billion, GAAP Diluted EPS of $0.90, and Non-GAAP Diluted EPS of $0.95 All Significantly Ahead of Expectations –. – Global Organic Molecular Diagnostics ex-COVID-19 Revenue Grows Over 20% in Constant Currency –. – Company Again Increases Full-Year Revenue and EPS Guidance –. MARLBOROUGH, Mass.

  7. Show article details.

    Earnings Scheduled For July 27, 2022

    Benzinga – 6:43 AM ET 07/27/2022

      ** Equinor is projected to report earnings for its second quarter. ** Alkermes is estimated to report quarterly earnings at $0.01 per share on revenue of $269.00 million. ** Imperial Ptrl is estimated to report earnings for its second quarter. ** Stifel Financial is projected to report earnings for its second quarter.

  8. Show article details.

    Earnings Scheduled For July 27, 2022

    Benzinga – 4:43 AM ET 07/27/2022

      ** Equinor is projected to report earnings for its second quarter. ** Alkermes is estimated to report quarterly earnings at $0.01 per share on revenue of $269.00 million. ** Imperial Ptrl is estimated to report earnings for its second quarter. ** Stifel Financial is projected to report earnings for its second quarter.

  9. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022

    Benzinga – 10:10 AM ET 07/20/2022

    B of A Securities upgraded the previous rating for Check Point Software Technologies Ltd from Underperform to Buy. According to Stifel, the prior rating for Franco-Nevada Corp was changed from Hold to Buy. According to Stifel, the prior rating for Xylem Inc was changed from Hold to Buy. According to HSBC, the prior rating for Chevron Corp was changed from Hold to Buy.

  10. Show article details.

    Analyst Ratings for Hologic

    Benzinga – 10:01 AM ET 07/18/2022

    Within the last quarter, Hologic has observed the following analyst ratings: According to 5 analyst offering 12-month price targets in the last 3 months, Hologic has an average price target of $80.0 with a high of $85.00 and a low of $75.00. Below is a summary of how these 5 analysts rated Hologic over the past 3 months.

  11. Show article details.

    Hologic Showcases Advances across the Continuum of Breast Health at ECR 2022

    Business Wire – 8:00 AM ET 07/13/2022

    --Global Leader in Women's Health Highlights Importance of Timely and Accurate Diagnosis-- Hologic, Inc. (HOLX) will showcase their comprehensive portfolio of breast and skeletal health solutions at the annual European Congress of Radiology in Vienna, Austria from July 13-17.

  12. Show article details.

    Hologic Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV

    Business Wire – 8:00 AM ET 07/11/2022

    --New assays for the Panther Fusion and Novodiag Systems further build on Hologic’s leading molecular scalable solutions offering to European customers-- Hologic, Inc. (HOLX) announced today that it is now offering its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag® RESP-4 molecular diagnostic test for sale in the European Union in time for the northern hemisphere’s respiratory viral se...

  13. Show article details.

    Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022

    Business Wire – 4:04 PM ET 07/05/2022

    Hologic, Inc. (HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2022 on Wednesday, July 27, after the market closes. Interested participants may listen to the call by dialing 289-0720 or +1 701-0160 and referencing access code 6025981.

  14. Show article details.

    New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options

    Business Wire – 8:05 AM ET 07/01/2022

    Hologic Taking Action with 'Hey, U!' Campaign to Educate Women in Conjunction with Fibroid Awareness Month A new survey commissioned by Hologic, Inc. (HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options.

  15. Show article details.

    Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients

    Business Wire – 8:02 AM ET 05/25/2022

    -- New quantitative assays for Epstein-Barr Virus and BK Virus expand Hologic’s Panther Fusion transplant pathogen monitoring menu -- Hologic, Inc. (HOLX) announced it has received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.

  16. Show article details.

    Expert Ratings for Hologic

    Benzinga – 11:14 AM ET 05/17/2022

    Analysts have provided the following ratings for Hologic within the last quarter: These 6 analysts have an average price target of $80.0 versus the current price of Hologic at $78.765, implying upside. Below is a summary of how these 6 analysts rated Hologic over the past 3 months.

  17. Show article details.

    CNBC's Final Trades: Charles Schwab And These 3 Medical Stocks

    Benzinga – 7:52 AM ET 05/12/2022

    On CNBC's "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management said Charles Schwab Corporation is trading at 14 times next year's earnings. Degas Wright of Decatur Capital Management cited Hologic, Inc. saying he likes the company for its "strong growth and diagnostics and imaging products." Check out other medical and tech stocks making big moves in the premarket.

  18. Show article details.

    15 Stocks Moved By Traders on 'Fast Money: Halftime Report'

    Benzinga – 1:52 PM ET 05/11/2022

    CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned.

  19. Show article details.

    Hologic's Return On Capital Employed Overview

    Benzinga – 9:57 AM ET 04/29/2022

    Pulled from Benzinga Pro data, Hologic posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters. Earnings data without context is not clear and can be difficult to base trading decisions on. It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool.

  20. Show article details.

    Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

    Benzinga – 3:18 PM ET 04/28/2022

    Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Page:

Today's and Upcoming Events

  • Oct
    31

    HOLX to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jul
    27

    HOLX announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.